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Objectives: Underlying mechanisms regulating angiogenesis in ovarian cancer have not
been completely elucidated. Evidence suggests that the TP53 tumor suppressor path-
way and tumor microenvironment play integral roles. We utilized microarray technology
to study the interaction betweenTP53 mutational status and hypoxia on angiogenic gene
expression.
Methods: Affymetrix U133A arrays were analyzed for angiogenic gene expression in 19
ovarian cancer cell lines stratified both by TP53 mutation status and A2780 wild-type (wt)
TP53 vs. mutated (m) TP53 cell lines after treatment under hypoxic conditions or with
ionizing radiation.
Results: Twenty-eight differentially expressed angiogenic genes were identified in the
mTP53 cell lines compared to wtTP53 lines. Five genes were upregulated in mTP53
cells: 40% involved in extracellular matrix (ECM) degradation [matrix metalloproteinase 10
(MMP10)/15] and 60% in angiogenesis (fibroblast growth factor receptor 3/VEGFA/ephrin
receptor-B4). Twenty-three genes were upregulated in wtTP53: nearly 22% were ECM
constituents or involved in ECM degradation; over 40% were growth factors or mediators
of angiogenesis. Five genes were upregulated in the A2780mTP53 cells: 40% involved
in ECM remodeling (MMP10, ADAMTS1), 40% with pro-angiogenic activity (EFNB2, fac-
tor 2 receptor), and 20% with anti-angiogenic properties (ADAMTS1). Three genes were
upregulated in hypoxia treated cells compared to controls: one with anti-angiogenic activity
(angiopoietin-like 4) and two with pro-angiogenic activity (VEGFA, EFNA3). No significant
gene fold changes were noted after exposure to radiation. Four genes continued to demon-
strate significant differential expression (p≤0.05) after adjusting for multiple comparisons.
These genes included endoglin upregulation in wt lines (pro-angiogenesis) and upregulation
of FGF20 (growth factor), ADAMTS1 (anti-angiogenesis) and MMP10 (ECM degradation)
in mTP53 cell lines.
Conclusion: Our exploratory findings indicate that non-overlapping angiogenic pathways
may be altered byTP53 mutations and hypoxic conditions in the tumor microenvironment.
Further evaluation is needed for confirmation.
Keywords: angiogenesis,TP53, ovarian carcinoma, hypoxia,VEGF
INTRODUCTION
The underlying mechanisms that regulate angiogenesis in ovarian
cancer have yet to be elucidated but most likely involve interactions
controlled by tumors and their microenvironment. Angiogenesis
is a complex multistep process that includes increased vascu-
lar permeability and dilation followed by extracellular matrix
(ECM) degradation; subsequent endothelial cell proliferation and
migration; formation of endothelial tubes; and recruitment of per-
icytes to support the neovasculature. Both tumor and host tissues
produce angiogenic factors that influence endothelial cell devel-
opment and migration (1). The vascular endothelial growth factor
(VEGF) family (VEGF-A, -B, -C, FIGF) and fibroblast growth fac-
tor 2 (FGF2) are fundamental growth factors in the process of
angiogenesis with VEGF-A having the most pro-angiogenic activ-
ity. VEGF promoter activity,VEGF mRNA levels, and FGF2 mRNA
expression have been shown to be downregulated by wild-type
(wt) TP53 (2–4). In mutant (m) TP53 it has been demonstrated
that hypoxia inducible factor 1 (HIF1) dependent transcriptional
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activation of VEGF gene expression has been enhanced (2). TP53
dysfunction has also been associated with increased tumor angio-
genesis based on microvessel density (MVD) by immunohisto-
chemistry (IHC) (5, 6). These findings indicate that TP53 may
play a role in the regulation of angiogenesis in ovarian cancer.
Hypoxic conditions in the tumor microenvironment have
been shown to stimulate angiogenesis in prostate (7), breast (7),
melanoma (8), and renal cancer (9). As the distance from tumor
to blood supply is increased, the leading edge of the tumor
becomes hypoxic, and in turn, induces the expression of the
HIF1/hypoxia regulatory element (HRE) complex, a key transcrip-
tion factor. HIF1α is considered a key regulator of angiogenic
factors. HIF1/HRE is responsible for increased gene expression of
numerous genes involved in angiogenesis, cell proliferation, and
matrix metabolism (10).
In order to investigate the interaction between tumor mole-
cular biology and the microenvironment on the regulation of
angiogenesis in ovarian cancer, we utilized genome-scale mole-
cular technology. Our results can enhance our understanding of
the molecular profiles of ovarian cancer tumor microenvironment
and link crucial processes such as angiogenesis, hypoxia, and per-
fusion; all of which are established factors in tumor aggressiveness
and resistance to therapy. Our primary objective was to determine
if angiogenic genes are differentially expressed in ovarian cancer
cell lines containing wt vs. mTP53 genes. We also sought to investi-
gate angiogenic gene expression patterns after simulated induction
of TP53 and hypoxia-related pathways. Our goal was to identify
novel angiogenic targets that may be exploited for therapeutic
purposes.
MATERIALS AND METHODS
OVARIAN CANCER CELL LINES
Eighteen immortalized ovarian cancer cell lines maintained by the
Duke Gynecologic Oncology research labs (Table 1) were sustained
in monolayer culture in RPMI 1640 with 10% fetal bovine serum,
sodium pyruvate, glutamine, and non-essential amino acids in
5% CO2 humidified chambers. Cell line authentication was per-
formed using the AmpFlSTR® Identifiler® Plus PCR Amplification
Kit (Applied Biosystems, Carlsbad, CA, USA) at the University
of Colorado Cancer Center, DNA Sequencing, and Analysis Core
(11). The STR genotypes of ovarian cancer cell lines that are avail-
able from the American Type Culture Collection or the RIKEN
BioResource Center Cell Bank were identical to the source geno-
types as reported within their respective STR databases and all
other non-commercially available cell lines were shown to be
derived from females with unique genotypes. The A2780wtTP53
and A2780mTP53 cell lines were obtained from Professor Robert
Brown B.Sc., Ph.D., of the Department of Medical Oncology, Uni-
versity of Glasgow. Protein extractions were performed as previ-
ously described (12). All experiments were performed in duplicate
or quadruplicate with appropriate controls.
HYPOXIA AND RADIATION TREATMENT OF CELL LINES
A2780 cell lines were grown to 80% confluence in T150 flasks and
exposed to hypoxic conditions using 5% O2 in a Bactron Anaerobic
Chamber (Sheldon Manufacturing, Cornelius, OH, USA) for 8 or
24 h prior to harvesting. For radiation exposure, the A2780wtTP53
Table 1 | Immortalized ovarian cancer cell lines stratified byTP53
status.
Wild-typeTP53 cell lines MutatedTP53 cell lines
A2780 parent cell linea A2780 mutant cell linea
DOV13 Fuov1
HEY TOV112D
HEYA8 OV90
HEYC2 OVCAR10
OVCA429 OVCAR3
TOV21G OVCA432
PEO1
PEO4
IGROV1
OVCA420
Tyknu
TyknuCisR
aThe A2780 cell lines (parent and mutant) were not included in the larger
microarray analysis. These cell lines were evaluated separately.
and A2780mTP53 cell lines were plated in 60 mm dishes, exposed
to 5 Gy of ionizing radiation for 900 s using the Gammacell 1000
(MDS Nordion, Ottawa, ON, Canada) and harvested at 0, 2, 4, 6, 8,
24,and 48 h. Western blots were performed to evaluate p53 and p21
protein expression per established protocols (12). The following
antibodies were used: p53 (sc-126, mouse monoclonal, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), p21 (AB-11, mouse mon-
oclonal, NeoMarkers, Fremont, CA, USA), actin (A4700, mouse
monoclonal, SIGMA, St. Louis, MO, USA), and goat anti-mouse
secondary antibody (Jackson ImmunoResearch, West Grove, PA,
USA).
MICROARRAY SAMPLE PREPARATION
Total RNA was used for probe generation and hybridization to
Affymetrix U133A GeneChip arrays as has been described previ-
ously in detail (13, 14). The microarray data was screened to select
for 378 probe sets belonging to angiogenic candidate genes on the
array, based on literature review. Expression patterns were com-
pared between: (1) wtTP53 vs. mTP53 ovarian cancer cell lines; (2)
hypoxia treated and untreated controls using the A2780wtTP53
and A2780mTP53 cell lines; (3) radiated A2780wtTP53 after 8 h
of exposure and untreated controls. The 8-h sample was cho-
sen because p53 protein expression after radiation exposure was
highest between 6 and 8 h (Figure 1).
STATISTICAL METHODOLOGIES
Microarray expression was calculated using the robust multi-
array average (RMA) algorithm implemented in the affy package
(15) of the Bioconductor (16) extensions to the R statistical pro-
gramming environment (http://www.R-project.org). RMA gener-
ates a background-corrected and quantile-normalized measure of
expression on the log2 scale of measurement. The ovarian cancer
cell line data, and that generated from the different A2780 con-
ditions, were each analyzed separately in this manner. For each
probe set on the array, we used a moderated T -statistic from the
limma package (17) to identify differential expression between
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FIGURE 1 |TP53 and p21 protein expression in radiated (R) vs. control
(C) in A2780 cell line. (A) Wild-type A2780 cell line shows increased TP53
expression in radiated vs. control samples. (B)TP53 mutant A2780 cell line
with induction of TP53 expression in radiated vs. control samples. TP53
protein expression increase seen at 4 h, with greatest increase at 6–8 h,
and induction sustained to 48 h. (C) p21 protein expression in wild-type
cells. Increased expression noted at 4 h and sustained to 48 h. (D) p21
expression inTP53 mutant cell line. Induction of expression noted at 4 h,
sustained to 48 h.
the wt and mTP53 genotypes. To identify differential expression
between the wt and mutant TP53 A2780 cell lines, hypoxia treated
cells, and radiated cells, we fit a three way analysis of variance
(ANOVA) model with fixed effects for genotype, treatment, and
batch for each probe set on the array. Thus genotype effects are
treatment and batch corrected, while treatment effects are geno-
type and batch corrected. The untreated A2780wtTP53 samples
served as the baseline for this analysis. The Holm–Bonferroni
method was used to correct for multiple hypothesis testing. Can-
didate genes with an unadjusted p-value <0.05 and an absolute
value log2 fold change (L2FC) >1.0 were identified. With these
candidate genes, a two-sample t -test was used to analyze the gene
expression data available in The Cancer Genome Atlas (TCGA)
database. The Benjamini–Hochberg method was used to control
the false discovery rate. Clustering of genes for heatmap presenta-
tion was done using a correlation distance metric on the z-score
normalized expression values.
RESULTS
ANGIOGENIC-RELATED GENE EXPRESSION IN OVARIAN CANCER CELL
LINES
Eighteen ovarian cancer cell lines with known TP53 genotype (wt
vs. m) were analyzed (Table 1). Of the 378 angiogenic candidate
gene probes identified during literature review, 28 (7.4%) were
found to be differentially expressed in cell lines with wt vs. mTP53
genotype status (Table 2; Figure 2). Five genes (five probe sets)
were considered upregulated in the mTP53 cell lines compared
to those with a wtTP53 gene given our initial threshold of a p-
value ≤0.05 and an absolute value L2FC ≥1. This list includes
fibroblast growth factor receptor 3 (FGFR3) (7.0 FC), matrix metal-
loproteinase 10 (MMP10) (5.7 FC), VEGFA (3.2 FC), MMP15 (2.5
FC), and ephrin receptor-B4 (EPHB4) (2.0 FC). After correcting
for multiple hypothesis testing, none of the genes were considered
significant at an adjusted p-value <0.05.
Twenty-three genes (43 probe sets) were upregulated in the
wtTP53 relative to the mTP53 cell lines including connective tis-
sue growth factor (CTGF) (14.0 FC), Serpine Peptidase Inhibitor,
Clade E, Type 1, Member 1 (SERPINE1) (14.0 FC), plasmino-
gen activator urokinase-type (PLAU ) (13.0 FC), CD44 (11.3 FC),
thrombospondin 1 (THBS) (9.8 FC), neuropilin 1 (NRP1) (9.2 FC),
alanyl aminoopeptidase (ANPEP) (9.2 FC), endoglin (ENG) (8.6
FC), transforming growth factor alpha (TGF-α) (8.6 FC), collagen
type IV alpha 2 (COL4A2) (8.0 FC), COL4A1 (7.0 FC), and FGF2
(5.3 FC) (Table 2; Figure 2). Only ENG was significant at a p-value
of 0.01 after correcting for multiple hypothesis testing.
ANGIOGENIC-RELATED GENE EXPRESSION IN TP53 wt AND MUTANT
A2780 OVARIAN CANCER CELLS
The A2780 cell lines differ only by a single TP53 gene mutation
and, therefore, allowed for isolation of differences in gene expres-
sion related to this TP53 mutation. Five genes were upregulated
in the A2780mTP53 compared to A2780wtTP53 cells, including
MMP10 (5.3 FC), FGF20 (2.8 FC), A disintegrin-like and met-
alloprotease with thrombospondin type 1 motif (ADAMTS1) (2.8
FC), ephrin B2 (EPHB2) (2.3 FC), and coagulation F2R (2.0
FC) (Table 3). FGF20 (adjusted p< 0.001), MMP10 (adjusted
p= 0.004), and ADAMTS1 (adjusted p< 0.001) were still con-
sidered significant after adjusting for multiple hypothesis testing.
In contrast, the A2780wtTP53 line demonstrated an upregulation
in three genes: VEGFC (2.5 FC), hypoxia inducible factor 1 alpha
(HIF1A) (2.3 FC), and angiopoietin-like 4 (ANGPTL4) (2.1 FC)
(Table 3).
Hypoxia exposure
Hypoxia treatment did not increase p53 protein expression
(Figure 3). A small increase in p21 protein expression was noted
in the TP53 mutant at the 8-h timepoint. This, however, was not
sustained at 24 h (Figure 3). Three angiogenic genes were upreg-
ulated in hypoxia treated A2780mTP53 cells when compared to
A2780wtTP53 controls, including VEGFA (3.5 FC),ANGPTL4 (2.8
FC), and ephrin A3 (EPHA3) (2.1 FC) (Table 3; Figure 4). No genes
were identified as upregulated in the A2780wtTP53 when exposed
to hypoxia.
Radiation exposure
TP53 protein expression increase seen at 4 h, with greatest increase
at 6–8 h (both mutant and wt), and induction sustained to 48 h.
p21 showed a similar induction of expression, starting at 4 h and
sustained to 48 h, in both wt and mutant cell lines (Figure 1).
Exposure to radiation did not yield any significant differen-
tially expressed genes when comparing the A2780mTP53 cells to
A2780wtTP53 controls.
TCGA DATABASE
The 36 candidate genes were then investigated using cell line data
available through the TCGA database. Given that the majority of
ovarian cell lines in the database had missing or discordant TP53
status, we looked at cell lines from multiple solid tumor types.
Again, after accounting for inconclusive TP53 status and those
without gene expression data, 44 cell lines were available for analy-
sis. mRNA expression data between mutant and wt TP53 was then
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Table 2 | Angiogenic genes that are differentially expressed in ovarian cancer cell lines harboring a mutantTP53 gene compared to those with
an intact wild-typeTP53 gene.
Gene Gene name Function Probe p-Value Adjusted
p-value
Log2 fold
change
Fold
change
GENES UPREGULATED IN MUTANTTP53 CELLS LINES COMPAREDTO WILD-TYPETP53 CELL LINES
FGFR3 Fibroblast growth factor receptor 3 Tyrosine kinase receptor 204379_s_at 0.007 0.10 2.8 7.0
MMP10 Matrix metallopeptidase 10 ECM degradation 205680_at 0.04 0.22 2.5 5.7
VEGFA Vascular endothelial growth
factor-A
Growth factor, angiogenesis 210512_s_at 0.008 0.10 1.7 3.2
MMP15 Matrix metallopeptidase-15 ECM degradation 203365_s_at 0.05 0.23 1.3 2.5
EPHB4 Ephrin receptor-B4 Tyrosine kinase receptor; vascular
development
202894_at 0.002 0.08 1.0 2.0
GENES UPREGULATED IN WILD-TYPETP53 CELLS LINES COMPAREDTO MUTANTTP53 CELL LINES
CTGF Connective tissue growth factor Mitogen secreted by endothelial
cells
209101_at 0.004 0.08 3.8 14.0
SERPINE1 Serpine peptidase inhibitor, clade
E, member 1
Fibrinolysis inhibition 202628_s_at 0.004 0.08 3.8 14.0
202627_s_at 0.02 0.13 3.1 8.6
PLAU Plasminogen activator urokinase ECM degradation 211668_s_at 0.003 0.08 3.7 13.0
205479_s_at 0.01 0.10 3.1 8.6
CD44 CD44 antigen Cell surface glycoprotein 212063_at 0.014 0.13 3.5 11.3
210916_s_at <0.001 0.05 3.0 8.0
212014_x_at 0.005 0.09 3.0 8.0
209835_x_at 0.007 0.10 3.1 8.6
204490_s_at 0.007 0.10 2.9 7.5
217523_at 0.016 0.13 1.8 3.5
204489_s_at 0.007 0.10 2.8 7.0
THBS1 Thrombospondin 1 Adhesive glycoprotein 201110_s_at 0.01 0.13 3.3 9.8
201109_s_at 0.01 0.13 3.3 9.8
201108_s_at 0.02 0.13 2.9 7.5
215775_at 0.05 0.22 1.1 2.1
ANPEP Alanyl aminopeptidase Metabolism of regulatory peptides 202888_s_at 0.03 0.19 3.2 9.2
NRP1 Neuropilin 1 Multifunctional membrane
receptor
212298_at 0.002 0.08 3.2 9.2
210510_s_at 0.015 0.13 2.1 4.3
ENG Endoglin, CD105 Endothelial cell surface protein 201809_s_at <0.001 0.01 3.1 8.6
201808_s_at <0.001 0.01 1.8 3.5
TGFA Transforming growth factor, alpha Growth factor 205016_at 0.003 0.08 3.1 8.6
COL4A2 Collagen, type IV, alpha 2 ECM constituent 211964_at 0.05 0.22 3.0 8.0
211966_at 0.03 0.18 2.3 4.9
(Continued)
Frontiers in Oncology | Women’s Cancer June 2014 | Volume 4 | Article 163 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Davidson et al. Differential gene expression in ovarian cancer
Table 2 | Continued
Gene Gene name Function Probe p-Value Adjusted
p-value
Log2 fold
change
Fold
change
COL4A1 Collagen, type IV, alpha 1 ECM constituent 211980_at 0.04 0.22 2.8 7.0
211981_at 0.02 0.13 2.7 6.5
IL1B Interleukin-1β Mediator of inflammatory
response
205067_at 0.002 0.08 2.8 7.0
39402_at 0.003 0.08 2.3 4.9
FGF2 Fibroblast growth factor 2 Growth factor 204422_s_at 0.003 0.08 2.4 5.3
204421_s_at 0.004 0.08 1.7 3.2
SPHK1 Sphingosine kinase 1 Kinase; anti-apoptotic pathways 219257_s_at 0.006 0.10 2.1 4.3
EFEMP2 EGF-containing fibulin-like
extracellular matrix protein
ECM protein 206580_s_at 0.018 0.13 1.9 3.7
209356_x_at 0.013 0.13 1.6 3.0
CXCL2 Chemokine ligand-2 Regulates hematopoietic
progenitor proliferation
209774_x_at 0.05 0.22 1.9 3.7
PLAUR Plasminogen activator, urokinase
receptor
ECM degradation 211924_s_at 0.04 0.20 1.8 3.5
F2R Coagulation factor 2 (thrombin)
receptor
G-protein coupled receptor,
mediates endothelial cells
activation
203989_x_at 0.008 0.10 1.5 2.8
NRP2 Neuropilin 2 Multifunctional membrane
receptor
211844_s_at 0.004 0.08 1.5 2.8
219367_s_at 0.004 0.08 1.2 2.3
EPHB2 Ephrin receptor-B2 Tyrosine kinase receptor; possible
tumor suppressor
209589_s_at 0.04 0.20 1.2 2.3
211165_x_at 0.03 0.19 1.2 2.3
EDIL3 EGF-like repeats and discoidin
I-like domains 3
Integrin ligand; mediates
angiogenesis
207379_at 0.03 0.19 1.2 2.3
ZFP36L1 ZFP ring finger protein-line 1 Regulates response to growth
factors
211962_s_at 0.02 0.13 1.1 2.1
EGFR Epidermal growth factor receptor Tyrosine kinase receptor; cell
signaling
211607_x_at 0.03 0.20 1.1 2.1
ECM, extracellular matrix.
compared. There was not a significant difference in expression
between the two groups for any of the candidate genes, though
NRP2 (upregulated in wt; p= 0.06) and MMP10 (upregulated in
mutant; p= 0.09) trended toward significance.
DISCUSSION
Understanding the underlying molecular and environmentally
responsive pathways driving angiogenesis can provide important
insight into the regulation of tumor angiogenesis, development
of resistance to VEGF-blocking agents and may assist in the
identification of novel targets to exploit in the development of
anti-angiogenic therapies. Our exploratory analysis indicates that
the regulation of angiogenesis is complex and may be under the
control of both TP53-dependent pathways and hypoxic condi-
tions. Furthermore, many of the genes identified are involved in
multiple facets of the angiogenic process, such as ECM degrada-
tion and remodeling; endothelial cell activation, migration, and
adhesion. While our data are exploratory in nature, there were
four genes that continued to demonstrate significant differential
expression even after adjusting for multiple comparisons. These
four differentially regulated genes included ENG (upregulated in
wt) and FGF20, ADAMTS1, and MMP10 (upregulated in mutant).
Matrix metalloproteinase 10 encodes a member of the matrix
metalloproteinase family of proteins that is responsible for base-
ment membrane degradation. MMPs are cysteine proteases with
zinc ion-dependent proteolytic activity that are involved prin-
cipally in the degradation of the ECM and subsequent tissue
remodeling (18–20). Our findings indicate that the intact TP53
tumor suppressor pathway may exert control via the regulation of
proteins involved in the ECM. The destruction of the basement
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FIGURE 2 | Heat map representing color-coded expression of
differentially expressed genes in 18 different wild-type or mutantTP53
cell lines. Twenty-eight genes exhibited statistically significant differential
expression by microarray analysis based onTP53 status.
membrane and the ECM is a fundamental step in the process
of tumor angiogenesis. Forty percent of the upregulated genes
identified in the mutated TP53 cell lines were involved in ECM
degradation (MMP10 and MMP15). MMPs are also upregulated
in response to cytokines, hormone, and growth factors, including
VEGF (21–23). Conversely, MMPs can also regulate the activity
of various growth factors, again including VEGF (24), as well as
chemokines, cytokines, and cell surface adhesion receptors. These
components are involved in cell migration and intracellular com-
munication that are directly implicated in wound healing, angio-
genesis, tumor progression, and metastasis (18–20, 25, 26). The
induction of MMP15 (also known as membrane-type-2 MMP)
has been shown to positively correlate with ovarian tumor metas-
tases in murine xenographs (27). MMP15 has also been postulated
to have a role in anti-apoptotic pathways, though the precise
mechanisms remain unknown (28). MMP10 was also significantly
upregulated in mutant A2780 TP53 vs. wt cell lines and mar-
ginally upregulated in the TCGA mutant TP53 vs. wt cell lines.
Furthermore, MMP10 has been shown to be highly expressed in
breast (29), prostate (30), and cervical cancer (31). Compared to
epithelial ovarian cancer (EOC), TP53 mutations in these par-
ticular malignancies are much less common (32). In a study of
head and neck squamous cell malignancies, TP53 mutations were
strongly associated with MMP-9 overexpression with a subsequent
increase in mean vessel density (33) while elevated p53 levels were
associated with decreased MMP-2 levels in patients with invasive
breast cancer (34). The notable upregulation of a number of mem-
bers of the MMP family in mutated TP53 cell lines indicates that
deregulation of the TP53 pathway may play an integral role in
ECM remodeling during tumor angiogenesis.
We found that several members of the FGF pathway exhib-
ited differential expression. This pathway is comprised of over 20
ligands and 4 tyrosine kinase receptors (FGFRs). Selected FGF
growth factors activate the FGFRs in conjunction with heparan
sulfate proteoglycans leading to the regulation of cell differen-
tiation, angiogenesis, cell motility, invasion, and survival (35).
FGF20 was recently identified and may have a potential role in
tumor growth and metastasis (36). Forced expression of FGF20
resulted in increased DNA synthesis, cellular proliferation, in vitro
transformation, and in vivo tumor growth (36). There is con-
flicting data regarding FGF20 expression in ovarian cancer. Our
data indicated that FGF20 is expressed in ovarian cancer cell
lines and was upregulated in the A2780mTP53 ovarian cancer
cells compared to the A2780wtTP53 cells. However, in the study
conducted by Jeffers et al. FGF20 mRNA was not expressed in nor-
mal ovarian tissue or the six studied ovarian cell lines (OVCAR3,
SKOV3, OVCAR4, OVCAR5, IGROV1, OVAR8) (36). In contrast,
Chamorro et al. reported that FGF20 is significantly elevated in
EOC cells harboring mutations in the WNT/B-catenin signal-
ing pathway (37). FGFR3 expression may also have an important
role in cancer progression. Our data show a sevenfold increase
in FGFR3 expression in mutant TP53 lines, consistent with Kim
et al.’s finding that inhibition of FGFR3 increased target cell
apoptosis and decreased resistance to targeted drug therapy (38).
FGFR3 overexpression has also been correlated with shorter dis-
ease free intervals and overall survival in patients with subtypes of
bladder malignancies (39).
In contrast, we found that FGF2 was upregulated in A2780
wt TP53 (5.3 FC) compared to mutant cells. We previously
reported that relative high FGF2 protein expression was asso-
ciated with a significant decreased risk of disease progression
and death in women with advanced ovarian cancer treated with
taxane and platinum-based therapy. Upon multivariate analy-
sis, however, the association between FGF2 and clinical outcome
was no longer significant (40). In addition, we did not detect an
association between FGF2 expression and TP53 mutation status
or protein expression (40). In our prior study of FGF2, we used
immunoblot technology and were unable to assess whether FGF2
is located in the stromal or cellular compartment. Our current
study evaluated FGF2 only in cell lines and does not account
for stromal expression of FGF2 protein. FGF/FGFR signaling is
Frontiers in Oncology | Women’s Cancer June 2014 | Volume 4 | Article 163 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Davidson et al. Differential gene expression in ovarian cancer
Table 3 | Angiogenic genes that are differentially expressed in the A2780 wild-type and mutantTP53 ovarian cancer cell lines and after
treatment with hypoxia.
Gene symbol Gene name Function Probe p-Value Adjusted
p-value
Log2 fold
change
Fold
change
GENES UPREGULATED IN MUTANT A2780TP53 CELLS LINES COMPAREDTO WILD-TYPE A2780TP53 CELL LINES
MMP10 Matrix metallopeptidase 10
(stromelysin 2)
ECM degradation 205680_at <0.001 0.004 2.4 5.3
FGF20 Fibroblast growth factor 20 Neurotrophic factor 220394_at <0.001 <0.001 1.5 2.8
ADAMTS1 A disintegrin and
metalloproteinase with
thrombospondin motif 1
Anti-angiogenic activity, ECM
remodeling
222162_s_at <0.001 <0.001 1.5 2.8
EFNB2 Ephrin B2 Endothelial cell adhesion 202668_at 0.001 0.27 1.2 2.3
F2R Coagulation factor 2 (thrombin)
receptor
G-protein coupled receptor,
mediates activation of endothelial
cells
203989_x_at 0.006 1 1.0 2.0
GENES UPREGULATED IN WILD-TYPE A2780TP53 CELLS LINES COMPAREDTO MUTANT A2780TP53 CELL LINES
HIF1A Hypoxia inducible factor 1 Regulates cell response to hypoxia 200989_at <0.001 0.09 1.2 2.3
VEGFC Vascular endothelial growth
factor-C
Growth factor, angiogenesis 209946_at 0.001 0.2 1.3 2.5
ANGPTL4 Angiopoietin-like 4 Inhibits vascular growth, tumor
cell invasion
221009_s_at 0.02 1 1.1 2.1
GENES UPREGULATED BY HYPOXIA vs. CONTROL
VEGFA Vascular endothelial growth
factor-A
Growth factor, angiogenesis 211527_x_at 0.002 0.9 1.6 3.0
212171_x_at 0.003 1 1.2 2.3
210513_s_at 0.003 1 1.4 2.6
210512_s_at 0.001 0.4 1.8 3.5
ANGPTL4 Angiopoietin-like 4 Inhibits vascular growth, tumor
cell invasion
221009_s_at 0.009 1 1.5 2.8
EFNA3 Ephrin A3 Endothelial cell migration and
adhesion
210132_at 0.002 0.8 1.1 2.1
very complex and function may vary based on the interaction
of the specific FGF ligand and the FGFR variant as well as reg-
ulatory factors in the tumor and microenvironment (35). Galy
et al. elegantly demonstrated that p53 protein directly repressed
FGF2 mRNA translation (41). These findings highlight limita-
tions with our microarray analysis. A single microarray analysis
cannot capture transcription variances or translational protein
alterations. Further exploration is needed to determine if the TP53
pathway is involved in the coordinated regulation of FGF family
members.
Our paper is the first to report a potential relationship between
TP53 mutation status and ADAMTS1 expression in ovarian can-
cer. In our study, ADAMTS1 was found to be upregulated in
A2780mTP53 cell lines compared to wt. ADAMTS1 is active in
ECM degradation and remodeling (42, 43) and has been impli-
cated in normal ovarian follicular development (44). Collagen
IV, as well as other basement membrane structural proteins, are
poorly organized in ADAMTS1 null ovaries (43). ADAMTS1 may
also play a role in ovarian medullary vascular development (44)
and its absence leads to a delay in lymphatic development (43).
Conflicting evidence exists regarding ADAMTS1 expression in
malignancy. A study by Freitas et al. reported decreased ADAMTS1
expression in primary breast malignancies with forced knock-
down stimulating migration and invasion of tumor cells in vivo
(45). In contrast, others have reported significant upregulation
in breast malignancies with subsequent increase in metastatic
activity (46, 47). These contrasting findings may result from the
auto-proteolytic cleavage of ADAMTS1 with subsequent disparate
effects on tumor activity – the full length molecule displays pro-
tumor properties while its cleavage products, ADAMTS-1NTF and
ADAMTS-1CTF, exhibit anti-tumor activity. This cleavage process
is regulated by the rates of production and degradation of heparin
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FIGURE 3 | (A) p53 protein expression under hypoxic conditions and control
inTP53 wild-type and mutant A2780 cell lines. No changes in protein
expression seen at 8 or 24 h. (B) Effects of hypoxia on p21 expression in
A2780 cell line. In wtA2780 cell line, no induction of p21 expression was
seen under hypoxic conditions. In mA2780 cell line, hypoxia induced a small
increase in p21 expression at 8 h but was not present at 24 h.
sulfate proteoglycans in the tumor microenvironment (48). Our
findings suggest that ADAMTS1 regulation may also be controlled
via the TP53 pathway.
In contrast to the previous candidate genes with upregula-
tion in mutant lines, ENG was upregulated in the wtTP53 cell
lines. ENG (CD105) is a membrane protein overexpressed in
tumor-associated endothelial cells and is a marker of proliferat-
ing endothelial cells and surrogate for tumor angiogenesis. ENG
downregulation in human EOC lines results in decreased vascular
proliferation (49). Ziebarth et al. demonstrated that forced ENG
inhibition resulted in decreased cell viability, increased apoptosis,
induced double-stranded DNA damage, and increased cisplatin
sensitivity in ovarian cancer cell lines (50). In our study, ENG was
upregulated in the wt TP53 cell lines and was a surprising find-
ing given the association between increased ENG staining in MCV
or tumor-associated endothelial cells and advanced stage disease,
suboptimal cytoreduction (51), and increased disease progression
(52, 53). There are conflicting results regarding the association
between ENG and survival (51, 54, 55). High ENG expression
in combination with high transforming growth factor B lev-
els prior to chemotherapy have been associated with improved
overall survival (55) while others have reported either decrease
survival for those with the highest levels of ENG expression (51,
53) or no relationship at all (54). Previously, we used ENG stain-
ing to determine MVD. We did not find an association between
ENG MVD and TP53 gene mutation status or protein expres-
sion (52). The difference between our two studies may be due
to the disparate study design (cell lines vs. tumor tissue) and/or
methodology (gene vs. protein expression; which may not cor-
relate) as well as the amount of stromal tissue included in the
tumor tissues. Our current study evaluating ENG in cell lines
alone does not account for stromal expression of ENG protein
in the microvasculature. The association between ENG expression
and TP53 status in cell lines suggests that ENG may be regulated
FIGURE 4 | Heat map representing color-coded expression of
differentially expressed genes under hypoxic conditions and after
radiation. Numbers indicate multiple replicates performed for each sample.
Three genes showed statistically significant upregulation by hypoxia. No
change in gene expression was noted after radiation.
by the TP53 pathway, though other regulatory mechanisms may
also exist.
Our data also demonstrated differential regulation of other well
known angiogenic genes in the mTP53 cell lines. Most notably,
VEGFA was upregulated in the mTP53 cell lines and under hypoxic
conditions demonstrating the convergence of the VEGF path-
way by both mechanisms. VEGFA is known to be one of the
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most potent pro-angiogenic factors. There is conflicting litera-
ture regarding TP53 status and association with VEGF protein
expression in ovarian cancer specimens. Horiuchi and colleagues
reported no association between p53 and VEGF protein expres-
sion in ovarian cancers using IHC (56). Previously, we reported
an association between p53 protein overexpression and low VEGF
protein expression in advanced ovarian cancer specimens, but no
association between VEGF and TP53 mutation status (40). Upon
further assessment, we found that the association between p53
and VEGF protein expression was limited to the ovarian cancers
that contained a wt TP53 gene and lacked p53 protein expression
(40). The lack of VEGFA induction with ionizing radiation sug-
gests that higher VEGFA expression may be associated with TP53
mutations, but that TP53 may not be regulating VEGFA expres-
sion. In contrast, the VEGF pathway may be primarily regulated via
hypoxic conditions in the tumor microenvironment rather than
by TP53. It is well established in the literature that hypoxic con-
ditions increase VEGF expression (5, 10, 56, 57) with expression
increasing after exposure to hypoxia regardless of TP53 pathway
status. This suggests that hypoxia has a dominant role in VEGF
regulation (57).
Furthermore, other members of the VEGF family, such as
VEGFC and NRP1 and NRP2, were all upregulated in the cell lines
harboring wtTP53 compared to those with a mutant gene. NRP2
was also marginally upregulated in the TCGA wt TP53 cell lines
compared to mutant cell lines. VEGFC is an integral part of lym-
phangiogenesis and has been associated with lymph node metas-
tases and prognosis in a variety of malignancies (58–61). NRP1
and NRP2 interact with both VEGF ligands and class 3 semaphorin
(SEMA3) ligands in overlapping binding domains (62). While
VEGF promotes angiogenesis and interacts with NRP1 to enhance
the binding to its receptor, members of the SEMA3 family inhibit
angiogenesis (63). Specifically, SEMA3F binding to NRP2 inhibits
tumor angiogenesis and metastasis (63). NRP overexpression has
been reported in multiple solid malignancies including breast, gas-
trointestinal, and prostate tumors (63). Conflicting evidence exists
regarding NRP expression in ovarian tumors. Bednarek et al. stud-
ied NRP1 expression in 50 patients with EOC, the majority of
which had weak (n= 13) or no (n= 22) immunohistochemical
staining (64). In contrast, Baba et al. reported that 97% of EOC
tissue samples and 67% of cell lines stain strongly (65). Recently,
Stanton and colleagues reported that the VEGFC–NRP2 axis pro-
moted autophagy, which, in cancer, may represent an adaptive
response to promote cell survival (62).
Members of the ephrin family were also differentially expressed
in the cell lines and after exposure to hypoxia. The genes encod-
ing the ligand EFNB2 and the receptor EPHB4 were upregulated
in mutant TP53 cells; EFNB2 was upregulated in the A2780 line
and EPHB4 was upregulated in the larger pool of mutant TP53
lines. In contrast, the ephrin receptor, EPHB2, was upregulated in
wt TP53 cell lines while overexpression of the ligand, EFNA3, was
induced by hypoxia. Ephrin and the ephrin receptors are a fam-
ily of membrane-bound tyrosine kinases and receptor tyrosine
kinases (RTKs) that are typically highly promiscuous; most of the
receptors are capable of binding to numerous ephrin ligands (66,
67). Since both receptors and ligands are membrane-bound, the
receptor ligand interactions are capable of bi-directional signaling
(67). Members of the ephrin RTK family are expressed on both
tumor cells as well as the tumor endothelium and fibroblasts (68,
69). Data from targeted disruption of Eph RTKs and ligands in
mice have revealed that the ephrin pathway plays a critical role in
embryologic vascular development and tumor angiogenesis (70).
EFNA1 and EFNB2 are regulated by TP53 as well as other mem-
bers of the TP53 family, including p73 and p63 (71, 72). Hypoxia
upregulates both mRNA and protein expression of EPHB4,EFNB2,
EPHA2, and EFNA1 (73). EPHB4 RTK is expressed in 86% of
invasive ovarian cancers and was associated with advanced stage,
worse survival (74), and decreased response to chemotherapy (66).
EFNB1, an alternate ligand of EPHB4, has been associated with
increased MVD in EOC (75). The precise mechanism of ephrin-
mediated angiogenesis is unknown, but our data indicate that both
the TP53 tumor suppressor pathway and hypoxia may effect ephrin
family members.
In addition, we have evaluated our panel of angiogenic genes
in women with advanced, high grade serous ovarian carcinoma
whose tumors had undergone microarray analysis. We conducted
an extreme phenotype study that included women with long sur-
vival (>7 years) vs. short survival (<3 years) (76). Thirty-one
genes were significantly associated with clinical outcome includ-
ing several of the genes reported in our current study (CD44−,
EPHB2, HIF1A, NRP1, and TGFA). Of these, high CD44 was asso-
ciated with longer survival in the TCGA database. In contrast, high
expression of EPHB2 and NRP1 were associated with shorter sur-
vival in an external database (76). Microarray analysis of cell lines
may potentially identify genes that have prognostic significance
for survival.
Limitations of our study include the use of a simple model of
ionizing radiation to simulate TP53 induction (77, 78). To vali-
date our model, we irradiated ovarian cancer cell line OVCA420
to 5 Gy and then subjected cell lysates to immunoblot to assess
total p53 expression. When compared to non-irradiated cells,
irradiated cells demonstrated a 3.3-fold increase in p53 protein
expression 48 h after exposure (Figure 1). We acknowledge that
ionizing radiation likely induces other genes in addition to TP53
and these unidentified genes may also play a role in angiogenesis.
The in vitro nature of this investigation limits the application of
these results to more complex systems such as living organisms.
Specifically, cell lines lack the adjacent stroma that is integral to
evaluate mesenchymal remodeling, and tumor angiogenesis was
not assessed in this model. Another limitation of our study is
that while a number of genes showed a significant change in
expression, most were no longer significant after correcting the
p-values for multiple hypothesis testing. Thus, further verification
by another methodology is necessary to establish that these genes
are in fact differentially expressed and not the result of statisti-
cal error. Our study incorporates data from cell lines of various
epithelial ovarian histologies. Though it is well known that an
overwhelming majority of serous type tumors possess TP53 muta-
tions, a study by the Gynecologic Oncology Group suggests p53
overexpression may be seen in one-third of mucinous or clear cell
histologies while over 70% of tumors deemed “other” also possess
p53 overexpression (79).
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Despite these limitations the data generated from this study
confirmed the complexity of angiogenesis regulation and the
presence of convergent and divergent pathways controlled via
TP53-dependent and independent mechanisms representing how
genetic mechanisms and environmental conditions interact to
promote a pro-angiogenic environment. Identification of mul-
tiple members of the VEGF, FGF, MMP, and ephrin families as
well as other novel genes in our series indicates the existence of
multiple regulatory mechanisms involved in tumor angiogenesis.
The most differentially expressed genes in our panel represent
appealing therapeutic targets that may be exploited to develop
anti-angiogenic therapies.
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